High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Idiopathic Parafoveal Telangiectasia (IPT) [also known as Idiopathic Perifoveal
Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia
(MacTel)] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass
classification of macular telangiectasias (Reference 1,5) - a bilateral, but not always
symmetric disorder. It is characterized in its early stages by dilation and loss of
parafoveal capillaries accompanied by angiographic leakage, "right angle" venules, central
and parafoveal intraretinal cysts.